← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Nanoscope Technologies, Llc
Arlington, TX
$13,083,910
Total funding
8
Grants
Funding over time
peak $2.5M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,083,910 · 8
By mechanism
R44$7,362,618 · 3
R01$3,665,360 · 2
U01$1,571,637 · 1
R43$484,295 · 2
Investigators at Nanoscope Technologies, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Ambient light activatable opsin based therapy for age-related macular degeneration$1,031,182
R44 · FY2018 · EY
Ambient light activatable opsin based therapy for age-related macular degeneration$950,373
R44 · FY2019 · EY
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment$875,350
R44 · FY2023 · EY
Sonogenetic Restoration of Vision for Retinitis Pigmentosa$786,257
U01 · FY2025 · EY
Sonogenetic Restoration of Vision for Retinitis Pigmentosa$785,380
U01 · FY2024 · EY
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy$779,869
R44 · FY2020 · EY
Ambient light activatable opsin based therapy for age-related macular degeneration$749,517
R44 · FY2021 · EY
Ambient light activatable opsin based therapy for age-related macular degeneration$737,805
R44 · FY2022 · EY
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment$716,879
R44 · FY2022 · EY
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy$678,626
R44 · FY2021 · EY
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy$656,220
R44 · FY2022 · EY
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$493,520
R01 · FY2019 · EY
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$484,950
R01 · FY2019 · EY
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$387,500
R01 · FY2020 · EY
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$384,200
R01 · FY2020 · EY
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$375,875
R01 · FY2022 · EY
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$375,875
R01 · FY2021 · EY
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual system$274,200
R01 · FY2018 · EY
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$247,500
R01 · FY2018 · EY
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatment$247,500
R01 · FY2017 · EY